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ABSTRACT
Introduction: In October 2012, the Swedish Medical Products Agency published new recom-
mendations for the cessation of prophylactic antibiotics in dentistry for the prevention of
infective endocarditis (IE). Previously, 2 g of amoxicillin per os would be administered 1
h before invasive dental procedures to patients with valve prosthesis, complicated heart valve
disease, and to those with previous endocarditis.
Objectives: The aim of this study was to evaluate whether the total incidence of IE caused by
oral viridans group streptococci (VGS) or IE caused by staphylococci, increased in Sweden
after the introduction of the new recommendations.
Methods: The incidence of IE in Sweden before and after October 2012 was calculated and
compared using an interrupted time series analysis. Separate analyses were conducted for the
total incidence of IE, and IE caused by VGS or Staphylococcus aureus. Cases of IE were
identified using the Swedish national registry of IE, which has existed since 1995 and contains
data from all Swedish hospital clinics specialising in infectious disease. All cases with hospital
admission date from the 1st of Jan 2008, to the 31st of Dec 2017 were included. The incidence
calculations were corrected for annual changes in population size using data from the
Swedish government agency Statistics Sweden.
Results: The results show no statistically significant increase in the slope of the trend line of
the total incidence of IE, IE caused by VGS or S. aureus in the Swedish general population after
October 2012, compared to before.
Conclusion: The results suggest that the recommended cessation of prophylactic antibiotics
for the prevention of IE in dentistry has not led to an increased incidence of IE caused by oral
streptococci among the Swedish population.
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Infective endocarditis (IE) arises when the innermost
layer of the heart, the endocardium, is colonised by
microorganisms circulating in the blood [1]. The
colonisation is usually located to the heart valves,
where microorganisms subsequently form
a vegetation. As the disease progresses, it can lead
to heart failure and embolization of blood vessels
caused by circulating vegetation fragments [2]. The
disease is fatal if left untreated and associated with an
in-hospital mortality of 10–30% [1,3,4].
Treatment is focused on the eradication of
microbes by antimicrobial treatment alone or in com-
bination with surgery, and can require specialists in
several medical fields such as infection, cardiology
and thoracic surgery [1].
The most common pathogens causing IE are vir-
idans group streptococci (VGS); a group of alpha-
hemolytic bacteria commonly found in the oral cavity,
and staphylococci (Staphylococcus aureus and
Staphylococcus epidermidis), commonly found on the
skin [5]. VGS cause a slower and less aggressive pro-
gression of IE, with lower mortality, than staphylo-
cocci [5,6].
The incidence of IE in Sweden has been reported
to be 6.2–7.7 cases per 100 000 individuals per year
[4,7]. Ternhag et al. found an increasing incidence of
IE in Sweden from 1997 to 2007 [4]. Internationally,
the incidence of IE ranges from 2 to 7 cases per 100
000 individuals per year [1,8].
Healthy endocardium is usually resistant to colo-
nization, but disease and congenital malformations
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may result in damage of the endocardium causing
a predisposition for IE [5]. Previous endocarditis,
heart valve disease and prosthetic heart valves are
important risk factors for IE. Elderly patients
(>65 years of age) also have an elevated risk of IE.
This may be due to the clustering of risk factors and
the presence of undetected minor degenerative valve
lesions [1]. However, 40% of the patients developing
IE lack previously known heart disease [9–11].
The use of antibiotic prophylaxis (AP) in dentistry
for the prevention of IE is controversial. The purpose
is to reduce bacteraemia caused by invasive dental
treatment and prevent colonization of the endocar-
dium, thereby reducing the risk of IE [1]. However,
the efficacy of the prophylaxis has not been con-
firmed [12]. Bacteraemia caused by VGS is known
to occur not only after invasive dental treatment, but
also during daily dental activities such as tooth brush-
ing and flossing [13–17].
Current guidelines in Europe and America have
restricted the indications for AP in dentistry, stating
that it should be administered only to individuals
with the highest risk of developing IE [2,18–20]. In
Sweden, cessation of the prophylaxis to both low risk
and high risk patients groups has been recommended
since October 2012 [21].
In 2015, Thornhill et al. showed that a single dose
of 3 grams of amoxicillin was associated with a low
number of adverse drug reactions [22]. A restrictive
approach towards the use of AP is however supported
by data showing that one single dose of amoxicillin
can induce significant disruption in the oral micro-
biota, and cause selection of bacteria resistant to
antibiotics [23]. Antimicrobial resistance constitutes
an enormous threat to modern healthcare, because
numerous treatments require the use of effective anti-
biotics [24]. The association between the prescription
of antibiotics and antimicrobial resistance is undis-
puted, and great effort is focused on reducing the use
of antibiotics [25].
The benefits of a restrictive approach towards the
use of antibiotics must be weighed against the poten-
tial risks. Considering the severity of IE it is of utmost
importance to investigate the effect of refraining
from AP.
The aim of this study was to evaluate whether the
incidence of VGS-IE increased in Sweden after the




An interrupted time series analysis (ITSA) was con-
ducted of the monthly incidence of IE in the Swedish
general population from 2008 to 2017, in order to
calculate any increased incidence of the disease after
the recommended cessation of AP in dentistry for the
prevention of IE in October 2012. The change in
recommendations allowed comparison of the inci-
dence of IE caused by oral streptococci at a time
when antibiotics was – and was not – recommended
for the prevention of IE. Three separate analyses were
conducted of the incidence of 1) all cases of IE, 2) IE
caused by VGS, and 3) IE caused by S. aureus, in
order to calculate and compare pre- and post-
intervention trends. IE caused by VGS was consid-
ered to be of oral origin and thus of relevance with
regard to cessation of AP during invasive dental
procedures. The total incidence of IE and the inci-
dence of IE caused by S. aureus were analysed to
monitor trends in IE not related to the altered AP
recommendations. Patients included in the study ful-
filled the criteria for definite or possible IE according
to the modified Duke criteria [26].
Sources of data
Cases of IE were identified using the Swedish national
registry of IE (SRIE), with an estimated coverage of
88% of Swedish cases of IE. Detailed information of
the causative organism was available in 92% of cases.
Age and sex distribution in the SRIE is displayed in
Table 1, with the in-hospital mortality and propor-
tion causative microorganisms.
In 1995, the Swedish Society for Infectious
Diseases introduced a Swedish national registry of
IE (the SRIE). All 30 departments of infectious







n % n % n %
Age
Mean 64.5 65.2 64.9
Minimum 18 17 17
Maximum 99 100 100
Sex
Female 677 34 824 31 1501 32
Male 1308 66 1840 69 3148 68
Total 1985 100 2664 100 4649 100
Causative microorganism
VGS 497 25 653 25 1150 25
S. aureus 728 37 995 37 1723 37
Other 623 31 822 31 1445 31
Unknown 137 7 194 7 331 7
Total 1985 100 2664 100 4649 100
Mortality during treatment of
IE
VGS 28 6 38 6 66 6
S. aureus 115 16 113 13 248 14
Other 58 9 79 10 137 9
Unknown 8 6 15 8 23 7
Total 209 11 265 10 474 10
The table shows the in-hospital mortality of IE caused by viridans group
streptococci (VGS), Staphylococcus aureus, and other microorganisms
(mainly enterococci and coagulase-negative staphylococci). Data are
displayed separately for the period before and after the cessation of
antibiotics in dentistry for the prevention of IE, in October 2012.
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diseases (ID) in Sweden have participated in the
registry since its inception. These ID departments
have regional responsibility for the care of patients
with severe infections, and patients requiring acute
surgery for IE are, in most cases, treated in ID depart-
ments during the pre- and/or postoperative period.
All cases are reported on a standardized question-
naire at the time of discharge and a second question-
naire after follow-up (mean: 3 months after
treatment). Data regarding risk factors, presence of
prosthetic valve, type of prosthetic valve and presence
of other implantable cardiac devices is collected. The
origin of the etiologic agent is verified using, for
example, blood cultures, cultures from valves during
surgery, and polymerase chain reaction (PCR) from
tissue samples of valves. Information about antibiotic
treatment, need for surgery, and treatment outcome
is also included.
The registry has been used to present clinical data
regarding various pathogens [27–32] and has made
contributions to numerous studies within the frame-
work of the International Collaboration on
Endocarditis (ICE) with around 30 publications
[3,6,33].
Children and young adults from the age of 0 to
16 years are treated at paediatric clinics not reporting
to the register. However, the incidence of IE among
children has been reported to be lower than among
adults in Sweden [7,34]. We studied data from
January 2008 to 2017 which covered an approximate
period of 5-years before and 5-years after the recom-
mendations to cease AP.
The incidence calculation was corrected for annual
changes in the size of the Swedish population. The
Swedish population, above 16 years of age, increased
from 7 463 069 individuals in December (Dec) 2008,
to 8 107 436 in Dec 2017. Data on population size
was obtained from Statistics Sweden, the government
agency responsible for developing, producing and
disseminating official statistics and other government
statistics in Sweden. Data are collected by Statistics
Sweden on the 31st of December each year, and is
public and readily available in the statistical database
on their website [35].
Outcomes
The primary outcome measured in this study was the
incidence of VGS-IE in Sweden. In addition to this,
analyses were carried out on the total incidence of IE,
as well as the incidence of IE caused by S. aureus.
Statistical analysis
The statistical analysis was carried out using Stata/IC
15 (StataCorp. 2017. Stata Statistical Software: Release
15. College Station, TX: StataCorp LLC). We used the
ITSA module (Ariel Linden, 2014. ‘ITSA: Stata mod-
ule to perform interrupted time series analysis for
single and multiple groups,’ Statistical Software
Components S457793, Boston College Department
of Economics, revised 8 December 2017) to perform
a single group ITSA. The time of the intervention was
set to month number 59, corresponding to
October 2012, when the change in recommendations
for AP in dentistry was published by the Swedish
Medical Products Agency (MPA). Each point in the
ITSA represents the monthly incidence of
endocarditis.
Ethics
This study was approved by the Regional Ethical Review
Board, Karolinska Institutet, Stockholm, Sweden (ref:
2015/1910-31/1) prior to onset of the study.
An ethical permit and approval for the study was
also obtained from the register board of the SRIE,
before the collection of data.
Informed consent was waived because the study
does not pose any risk of physical harm to subjects,
no identifying information is published as results are
presented on group level only.
Results
Cases with known microbial aetiology not attributed
to VGS or S. aureus, were mainly caused by entero-
cocci (11%) and coagulase-negative staphylo-
cocci (6%).
Figure 1 shows the incidence of IE, by causative
microorganism across the study period. From
January (Jan) 2008 to Dec 2017, the incidence of
VGS-IE in Sweden varies between 5.2 and 22.0 cases
per 10 million individuals per month (Figure 1).
IE caused by VGS
After October 2012 there is a statistically significant
increase in the incidence of IE caused by VGS by
0.065 cases per 10 million individuals per month
(95% CI = [0.017, 0.114]) (Figure 2).
Comparison with the pre-intervention trend yields
a decrease in the slope of the trend line by −0.007
cases per 10 million individuals per month (95%
CI = [−0.085, 0.082]) after October 2012. This
decrease is not statistically significant.
The starting level is estimated to 8.9 cases/10 million
individuals/month in Jan 2008. The incidence appears
to increase by 0.072 cases per 10 million individuals
per month (95% CI = [−0.002, 0.146]) until
October 2012. This trend is not statistically significant.
Additional analyses were performed to account for
lag in adherence to the new recommendations.
Changing the time of intervention to 6, 12 or
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18 months after October 2012 did not yield any
statistically significant increase in the incidence of
VGS-IE, compared to the pre-intervention trend.
The total incidence of IE
There is a statistically significant increase in the inci-
dence of IE by 0.344 cases per 10 million individuals
per month (95% CI = [0.187, 0.502]) before
October 2012 (Figure 3). After October 2012, there
is also a statistically significant increase in the inci-
dence of IE, by 0.266 cases per 10 million individuals
per month (95% CI = [0.115, 0.416]).
Comparison of the trends shows a decrease in the
slope of the trend line after October 2012, relative to
the pre-intervention trend, by −0.079 cases per
10 million individuals per month (95%
CI = [−0.297, 0.139]). This decrease is not statistically
significant. The starting level is estimated at 33.7
cases/10 million individuals/month in Jan 2008.
Figure 1. Incidence of infective endocarditis (IE) in Sweden.
The incidence of all cases of infective endocarditis, cases caused by oral viridans group streptococci and Staphylococcus aureus in Sweden from
January 2008 to December 2017.
Figure 2. Single-group ITSA with Newey–West standard errors and one lag.
ITSA of the monthly incidence of infective endocarditis caused by viridans group streptococci in Sweden from Jan 2008 to Dec 2017.
Intervention is set to month 59, corresponding to October 2012. After October 2012 there is a decreasing trend, relative to the pre-intervention
trend, in the incidence by −0.007 points (95% CI = [−0.085, 0.082]). This trend is not statistically significant.
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IE caused by S. aureus
The incidence increases by 0.099 cases per 10 million
individuals per month (95% CI = [0.022, 0.176]) until
October 2012 (Figure 4). After October 2012, there is
a decrease in the slope of the trend line, relative to the
pre-intervention trend, by −0.012 cases per 10 million
individuals per month (95% CI = [−0.121, 0.096]).
This decrease is not statistically significant. The start-
ing level is estimated at 12.7 cases/10 million indivi-
duals/month. Intervention is set to month 59,
corresponding to October 2012. After October 2012
there is an increase in the incidence of IE caused by
Figure 3. Single-group ITSA with Newey–West standard errors and one lag.
ITSA of the monthly total incidence of IE in Sweden from Jan 2008 to Dec 2017. Intervention is set to month 59, corresponding to
October 2012. Comparison of the trends shows a decreasing trend after October 2012, relative to the pre-intervention trend, by −0.079
points (95% CI = [−0.297, 0.139]). This trend is not statistically significant.
Figure 4. Single-group ITSA with Newey–West standard errors and one lag.
ITSA of the monthly incidence of IE caused by Staphylococcus aureus in Sweden from Jan 2008 to Dec 2017. Intervention is set to month 59,
corresponding to October 2012. After October 2012, there is a decreasing trend, relative to the pre-intervention trend, in the incidence by
−0.012 points (95% CI = [−0.121, 0.096]). This trend is not statistically significant.
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S. aureus by 0.087 cases per 10 million individuals per
month (95% CI = [−0.011, 0.163]). This trend is not
statistically significant.
Discussion
To our knowledge, this is the first study of the inci-
dence of VGS-IE following the recommended cessa-
tion of AP in Swedish dentistry for the prevention of
IE in October 2012. The results imply that there was
no increase, over the predicted positive trend, in the
incidence of VGS-IE.
The UK and Sweden are the only countries to have
abandoned AP to individuals considered to be at high
risk of developing IE. Although in the UK, it is now
emphasised that the patient should make an informed
decision [36]. In Sweden, AP is in general prescribed
by the dentist, and the dentist is ultimately responsi-
ble for the decision to administer or not to administer
AP before dental procedures [21]. Previously in
Sweden, 2 g of amoxicillin per os had been recom-
mended 1 h before invasive dental procedures to
patients with valve prosthesis, complicated heart
valve disease, or previous endocarditis [21].
The number of prescriptions of amoxicillin by
Swedish dentists decreased by 20% in 2013 compared
to 2012 [37], and by 22.2% from 2013 to 2017 [38]. It
has been suggested that the decrease may be due to
the new recommendations [38].
The results of the current study show a statistically
significant increasing trend in the total incidence of
IE in Sweden both before and after October 2012. An
increasing incidence of IE across the general popula-
tion is in accordance with earlier studies of the epi-
demiology of IE in Sweden, USA, Italy, Taiwan and
Canada [39, 40, 41, 4, Mackie et al.]. The increase
may be due to increasing risk factors such as degen-
erative valve disease, receiving haemodialysis and
population ageing [4,39–41].
The results are consistent with those reported by
Thornhill et al in 2011 [42]. They excluded any statis-
tically significant increase in the incidence of IE in
England, during the 25 months after a cessation of AP.
In a later study however, Dayer et al. found an
increased incidence over the projected trend [43] in
England, and a 78.6% fall in AP prescribing.
Although they did not have access to detailed data
on the causative organism, and were unable to study
the incidence of VGS-IE.
Current European and American guidelines have
restricted the indications for AP in dentistry, stating
that it should be administered only to individuals
with the highest risk of developing IE [2,20].
Thornhill et al. published a review of studies mon-
itoring the impact of these restricted guidelines [44].
They found that several studies were limited metho-
dological flaws such as difficulties in accurately
identifying IE caused by oral VGS and a lack of
data on AP prescribing, and concluded that limiting
AP use to those at highest risk seems pragmatic and
appropriate.
Mackie et al. studied hospitalizations in Canada
due to IE before and after the publication of the
2007 AHA recommendations [45]. They found an
increasing trend before and after 2007. Comparison
showed no significant increase after 2007. They used
ICD codes to identify cases of streptococcal IE, but
were unable to identify cases caused by oral
streptococci.
The incidence of IE has been reported to be 2–7
cases per 100 000 individuals per year [1,8], which is
in accordance with our results based on the SRIE; 4 to
7 cases per 100 000 individuals per year. Ternhag
et al. utilized the Swedish patient register to calculate
the incidence of IE in Sweden from 1997 to 2007. We
found a similar male predominance among IE-
patients as in their study (40.8% females and 59.2%
males), but their incidence of IE was higher, at 7.7 per
100 000 individuals per year. Notably, our study was
not based on the patient registry, but on the SRIE.
It is possible that a calculation using the patient
registry could overestimate the incidence of cases of
IE in Sweden [4], while our calculation could under-
estimate it. There are two reasons for this. The first is
that the patient registry does not discriminate
between definite, possible and rejected cases of IE
according to the Duke criteria. For this reason,
there is a risk of misclassification leading to the
inclusion of rejected cases of IE. Secondly, the cover-
age of the patient registry is higher than that of the
SRIE.
The National Board of Health and Welfare
founded the patient registry in 1964, and it reached
full national coverage in 1987 [46]. The coverage of
the SRIE has been estimated to 88%.
One advantage of the SRIE is that it contains
detailed information on the microbiological aetiology
of cases of IE. For this reason, we were able to
calculate the incidence of VGS-IE, which is not pos-
sible using the patient registry. Future research could
integrate both registries to benefit from their respec-
tive advantages.
The short follow-up time after the change in
recommendations is one limitation, as the timeframe
may not be long enough to detect subtle effects on the
frequency of cases of VGS-IE. Despite this, ongoing
data monitoring is imperative after the change in
recommendations in Swedish dentistry.
Another limitation is that the microbial aetiology
is unknown in 7.7% of cases in the register. Reasons
for this are mainly that no blood culture was per-
formed, or that the performed blood culture showed
negative results. Additional analysis in the SRIE
showed that in 43% of cases with unknown aetiology,
6 N. VÄHÄSARJA ET AL.
a blood culture was performed but the results were
negative. Previous research concludes that in less
than 50% of cases where the blood culture was nega-
tive, this could be attributed to the administration of
antibiotics prior to the drawing of blood for a blood
culture [7]. Some of these cases could have been
caused by VGS, thereby resulting in an underestima-
tion of the incidence of IE with possible oral origin.
On the other hand the effect on our analysis should
be negligible, as it is unlikely that the microbial
aetiology for unknown cases should differ before
and after 2012.
A concern is that the study included all patients
regardless of high or low risk to develop IE after
invasive dental treatment. A study of a high-risk
population, such as valve prosthesis bearers, is
desirable.
The proportion of IE 1995–2012 caused by VGS,
recorded in SRIE, decreased from 35 to 25% and the
proportion of IE caused by S. aureus increased from
30 to 40%. These trends are in analogy with trends in
other countries with developed health care systems
and can make the results difficult to interpret.
Conclusions
The results suggest that the Swedish recommenda-
tions for the cessation of antibiotics in dentistry pub-
lished in October 2012 have not lead to an increase in
the incidence of IE in Sweden. Caution should be
taken when interpreting the results, due to a short
follow-up period, no specific analysis of high-risk
groups, such as patients with prosthetic valves, and
a limited number of cases.
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